Adheris Health (AHE) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
23 Nov, 2025Opening remarks and agenda
Meeting opened virtually with acknowledgment of traditional custodians and confirmation of quorum.
Notice of meeting included 14 ordinary resolutions, with voting and question procedures explained.
Shareholder proposals
Shareholders raised concerns about proxy disclosure, protest votes, and the complexity of incentive resolutions.
Questions addressed the fairness of executive benefits amid shareholder losses and low proxy participation.
Overview of voting outcomes
94 proxy forms received, representing about 43% of issued capital.
Significant protest votes recorded: 35% against resolution 1, 29% against resolution 4, 19% against CEO's incentive grant, and 59% against CEO's retention benefit.
Chair did not have enough open proxies to pass certain resolutions, particularly on executive retention payments.
Latest events from Adheris Health
- Significant revenue decline and US asset impairment led to a $60.2M net loss; ANZ business sold.AHE
H2 202525 Mar 2026 - Net profit surged to $7.35M on a $17.5M gain from the ANZ business sale; US is now the sole segment.AHE
H1 20268 Mar 2026 - Revenue down 45.8% year-over-year; cost cuts and new tech platform target recovery.AHE
Q2 2026 TU8 Mar 2026 - Revenue and profit fell sharply, prompting divestment and a focus on digital transformation.AHE
AGM 20253 Feb 2026 - Sharp 3Q declines offset by cost cuts and strong ANZ, with growth forecast for FY26.AHE
Q3 20253 Feb 2026 - Record profit, robust growth, and a five-year plan with strategic review to unlock value.AHE
AGM 202414 Jan 2026 - Revenue down 39% on US vaccine delays; margin and 2H outlook improve with cost savings ahead.AHE
Q2 20259 Jan 2026 - Revenue down 24% but margin and digital program mix improved; cost savings underway.AHE
H1 202526 Dec 2025 - ANZ business sold for up to AUD 42.35m; U.S. focus and leadership transition underway.AHE
Investor Update16 Nov 2025